Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus SUFENTA PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus SUFENTA PRESERVATIVE FREE.
ASTRAMORPH PF vs SUFENTA PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Sufentanil is a synthetic opioid analgesic that acts as a selective agonist at mu-opioid receptors in the central nervous system, leading to activation of descending pain pathways and inhibition of nociceptive transmission.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
1-2 mcg/kg IV initially, then 0.15-0.3 mcg/kg/min IV infusion; doses up to 8 mcg/kg for anesthesia induction.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal elimination half-life is approximately 2.5-3.5 hours in adults, 3-4 hours in neonates; clinical context: context-sensitive half-life increases with infusion duration (e.g., ~30 minutes after 2-hour infusion, ~45 min after 8-hour infusion).
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal (metabolites, <1% unchanged) and biliary; sufentanil is extensively metabolized in liver via N-dealkylation and O-demethylation, with metabolites primarily excreted in urine (approximately 80%) and feces (approximately 20%).
Category C
Category C
Opioid Analgesic
Opioid Analgesic